Medivir pares down its R&D efforts; Allergan faces another delay with bipolar drug;

@FierceBiotech: Pulmatrix hits Wall Street with $10M and a Mylan deal. Report | Follow @FierceBiotech

@JohnCFierce: Trending: Why did Briggs Morrison give up R&D leader role at $AZN to run a biotech? Story | Follow @JohnCFierce

@DamianFierce: I just watched Boyz II Men introduce BIO CEO Jim Greenwood and I'm dead now. | Follow @DamianFierce

> Medivir ($MVIR) is tightening its focus on oncology and infectious diseases, abandoning its work in neuropathic pain and shedding about 10 researchers in the process. The Swedish biotech is partnering with Indian CRO GVK Biosciences to handle much of its clinical workload in an effort to save money and speed up development. News

> Teva's ($TEVA) SD-809, a treatment for movement disorders, met its primary endpoint in a Phase III trial on tardive dyskinesia, the company said. More

> Allergan ($AGN) and partner Gedeon Richter will have to wait another three months for an FDA decision on the bipolar disorder treatment cariprazine, as the agency has extended its review period to September. Item

Medical Device News

@FierceMedDev: ICYMI: Sequenom slapped down in prenatal testing patent battle with Ariosa. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Indian feds stake out plan to become a global hub of device manufacturing and innovation. Story | Follow @VarunSaxena2

@EmilyWFierce: Researchers @TAMHSC are developing a test that could diagnose TB in 10 minutes. More from the WSJ | Follow @EmilyWFierce

> Philips, Siemens score big hospital bundling contracts, highlighting demand for value-based healthcare. Article

> Merck KGaA partner Genea gets CE mark for a pair of IVF technologies. Report

Pharma News

@FiercePharma: San Diego's BioAtla gets $30M from mystery Chinese investor in latest round. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: What's in a name? For newly transformed Allergan, branded sales. Article | Follow @CarlyHFierce

> Big Mylan shareholder Abbott backs Mylan's Perrigo buy. Story

> Survey: Americans say Big Pharma, not insurers, to blame for sky-high drug bills. Report

> AdverseEvents: Diabetes drug analysis flags heart failure, pancreatitis reports. Article

Pharma Manufacturing News

> Health Canada bans Hospira drugs coming from Italy plant. News

> Pam Cheng leaves Merck for top manufacturing job at AstraZeneca. Item

> India's Polydrug Labs criticized for contaminated APIs. More

> Pfizer supplements its China production with $90M plant. Story

> FDA upgrades standing of Jubilant U.S. sterile plant cited in 2013. Article

Drug Delivery News

> WHO adds postpartum contraceptive ring to 2015 essential meds list. Article

> Study finds Novo's tablet for vaginal atrophy increases compliance compared to creams. Item

> ADA: Nasal powder and artificial pancreas with glucagon both show potential. Story

> Biotie nets $56M+ in IPO, fellow Parkinson's player Cynapsus up next, followed by Intec Pharma. More

> Oculus receives FDA clearance for novel, spray-based wound care formulation. Report

Pharma Asia News

> Japan's PAFSC backs Lilly's dulaglutide, among others, in latest round. News

> NanoCarrier aims for PhI study on neck cancer in Japan for NC-6004. Report

> Video prescriptions, advice, on the cards for hard-pressed patients in Japan. More

> Deputy at China agency that probed GSK arrested for corruption, report says. Story

> China plans to ensure private hospitals get subsidies, finance. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.